Category Archives: NMS-E628

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014. It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

GRACE conference in Boston

There were several presentations as part of the Grace conference in Boston on Saturday, September 6. So far this is the only one I have found online. PowerPoint presentation by Dr. Alice Shaw on 8 or 9 new ALK inhibitors … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | 1 Comment

List of 9 ALK Inhibitors

List of 9 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Novartis – Ceritinib Pfizer – Crizotinib FDA Breakthrough Status Chugai – Alectinib (filed NDA in Japan) Ongoing trials Ariad AP26113 Nerviano NMS-E628. (Licensed by … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

LifeSci Advisors Initiates Coverage of Ignyta

Here is some information on Ignyta and it’s ALK inhibitor, RXDX-101, which was recently licensed from Nerviano. http://lifesciadvisors.com/news/lifesci-advisors-initiates-coverage-of-ignyta-inc/ http://lifesciadvisors.com/news/preliminary-data-from-ignytas-phase-iii-trial-presented-at-lung-cancer-meeting/

Posted in Lung cancer, NMS-E628, Research | Leave a comment

Ignyta enters exclusive worldwide license with Nerviano

In October 2013 Ignyta entered into an exclusive worldwide license with Nerviano for an ALK inhibitor drug candidate RXDX-101 (not clear if RXDX-101 is the same as NMS-E628 or different). Ignyta is a biotech startup in San Diego. Ignyta plans … Continue reading

Posted in Brain metastases, Lung cancer, NMS-E628, Research | Leave a comment

List of drugs in clinical trials

List of 10 ALK inhibitor drugs currently (or soon to be) in clinical trials: Ariad AP26113 Astellas ASP-3026 Chugai Alectinib (filed NDA in Japan) Nerviano NMS-E628. (Licensed by Ignyta and renamed RXDX-101) Novartis LDK-378 Pfizer Crizotinib (FDA approved but several … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, NMS-E628, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Update on Nerviano’s NMS-E628

http://www.nervianoms.com/en/oncology-en/pipeline/alk-inhibitor.html The following abstract states that NMS-E628 is currently in Clinical Trials. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3086&sKey=a8d46b5e-6302-4f23-ba8d-ef47308b63a8&cKey=bcf85f04-34cb-42b8-b466-d9ed578fbc51&mKey=%7B9B2D28E7-24A0-466F-A3C9-07C21F6E9BC9%7D

Posted in NMS-E628, Potential Treatments | Leave a comment